USP Welcomes New Partners to "Fight the Fakes" Campaign - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Welcomes New Partners to "Fight the Fakes" Campaign



As part of an ongoing international effort to battle counterfeit medicines, the US Pharmacopeial Convention (USP) welcomed 11 new organizations as partners in the global “Fight the Fakes” campaign.

“Counterfeit medicines can account for up to 30% of the drug supply in parts of Asia, Africa, and Latin America according to estimates from the World Health Organization (WHO),” said USP CEO Ron Piervincenzi.

Established in 2013, Fight the Fakes is a campaign to raise awareness about the dangers of fake medicines, giving a voice to those who have been personally impacted and sharing the stories of those working to put a stop to this public health threat. The Fight the Fakes initiative now includes 25 healthcare groups, research institutes, foundations, non-profits, and private sector organizations.

Source: USP

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here